MRNS - Marinus Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.6200
-0.0900 (-2.43%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close3.7100
Open3.6000
Bid3.46 x 4000
Ask3.78 x 4000
Day's Range3.5900 - 3.8300
52 Week Range3.3100 - 10.5400
Volume1,999,877
Avg. Volume1,260,158
Market Cap146.7M
Beta (3Y Monthly)5.27
PE Ratio (TTM)N/A
EPS (TTM)-0.87
Earnings DateJul 30, 2018 - Aug 3, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.83
Trade prices are not sourced from all markets
  • Marinus Pharmaceuticals plans $45M stock sale
    American City Business Journals3 days ago

    Marinus Pharmaceuticals plans $45M stock sale

    Based in Radnor, Marinus Pharmaceuticals is studying a potential treatment for postpartum depression and acute epilepsy.

  • GlobeNewswire3 days ago

    Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    Marinus Pharmaceuticals, Inc. (MRNS) (“Marinus” or the “Company”) announced the pricing of an underwritten public offering of 12,000,000 shares of common stock at a public offering price of $3.75 per share. The total public offering size is expected to be $45.0 million, before deducting the underwriting discounts and commissions and other offering expenses payable by the Company. The Company has granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 1,800,000 shares of common stock.

  • Here's Why Marinus Pharmaceuticals Is Sinking Today
    Motley Fool3 days ago

    Here's Why Marinus Pharmaceuticals Is Sinking Today

    A secondary offering on the way isn't what investors wanted to hear.

  • Benzinga4 days ago

    The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 11) Imprimis Pharmaceuticals Inc (NASDAQ: IMMY ) OvaScience ...

  • GlobeNewswire4 days ago

    Marinus Pharmaceuticals Announces Public Offering of Common Stock

    Marinus Pharmaceuticals, Inc. (MRNS), (“Marinus” or the “Company”) today announced that it intends to offer and sell 12,000,000 shares of its common stock in an underwritten public offering.  All of the shares in the offering are to be sold by Marinus.  Jefferies LLC and Leerink Partners LLC are acting as joint bookrunning managers for the offering. Marinus also expects to grant the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of common stock.  The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • Benzinga6 days ago

    Marinus Pharma's Postpartum Depression Candidate Aces Midstage Trials

    A handful of micro-cap stocks were making moves Monday, with the release of clinical trial results being the catalyst. Marinus said the Phase 2 trials that evaluated intravenous and oral ganaxolone for women with postpartum depression, or PPD, produced positive results.

  • GlobeNewswire6 days ago

    Marinus Pharmaceuticals Announces Positive Ganaxolone Data in Women With Postpartum Depression

    Marinus Pharmaceuticals, Inc. (MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders, today announced positive results from its Phase 2 clinical trials evaluating ganaxolone intravenous (IV) (the Magnolia Study) and oral (the Amaryllis Study) in women with postpartum depression (PPD). Based on these results, the Company is advancing both studies into the next phase of development to evaluate IV and oral dose regimens.

  • GlobeNewswire12 days ago

    Marinus Pharmaceuticals Phase 2 Clinical Trial Data Show Long-term Effectiveness of Ganaxolone in Reducing Seizure Frequency in CDKL5 Deficiency Disorder Patients

    Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that ganaxolone data from its Phase 2 clinical trial in pediatric genetic epilepsies, CDKL5 Deficiency Disorder (CDD) and PCDH19-related pediatric epilepsy (PCDH19 epilepsy) were presented at the American Epilepsy Society (AES) Annual Meeting in New Orleans on December 2 and 3, 2018.

  • GlobeNewswire27 days ago

    Marinus Pharmaceuticals to Present Ganaxolone Clinical Trial Data in CDKL5 Deficiency Disorder and PCDH19-Related Epilepsy at AES

    Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that two abstracts highlighting the results of clinical trials of ganaxolone in children with CDKL5 Deficiency Disorder (CDD) and PCDH19-related epilepsy have been selected for poster presentation at the American Epilepsy Society (AES) Annual Meeting in New Orleans on December 2 and 3, 2018.

  • Granite Point Capital’s Returns, AUM, and Holdings
    Insider Monkeylast month

    Granite Point Capital’s Returns, AUM, and Holdings

    Warren Lammert founded Granite Point Capital, a long/short hedge fund with a focus on small-cap companies, in January 2004. The fund is headquartered in Boston, Massachusetts, and Mr. Lammert is its portfolio manager. Prior to launching his own fund, Warren Lammert honed his investment acumen for 14 years at Janus Capital Management LLC as a […]

  • Is the Options Market Predicting a Spike in Marinus Pharmaceuticals (MRNS) Stock?
    Zackslast month

    Is the Options Market Predicting a Spike in Marinus Pharmaceuticals (MRNS) Stock?

    Investors need to pay close attention to Marinus Pharmaceuticals (MRNS) stock based on the movements in the options market lately.

  • GlobeNewswirelast month

    Research Report Identifies Oil States International, Brightcove, Electronics for Imaging, Cirrus Logic, Innoviva, and Marinus Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Nov. 06, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Associated Press2 months ago

    Marinus Pharmaceuticals: 3Q Earnings Snapshot

    The Radnor, Pennsylvania-based company said it had a loss of 27 cents per share. Marinus Pharmaceuticals shares have dropped 38 percent since the beginning of the year. The stock has dropped 16 percent ...

  • GlobeNewswire2 months ago

    Marinus Pharmaceuticals Provides Business Update and Third Quarter 2018 Financial Results

    RADNOR, Pa., Oct. 29, 2018 -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative.

  • GlobeNewswire2 months ago

    Marinus Pharmaceuticals Names Dr. Rolando Gutíerrez-Esteinou as VP of Clinical Development and Pharmacovigilance

    Marinus Pharmaceuticals, Inc. (MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced the appointment of Rolando Gutíerrez-Esteinou, M.D., as Vice President of Clinical Development and Pharmacovigilance where he will primarily be responsible for the medical leadership of our postpartum depression (PPD) programs and drug safety. “Dr. Gutíerrez-Esteinou is a welcome addition to the management team at Marinus,” said Christopher Cashman, Chairman and CEO of Marinus Pharmaceuticals.

  • GlobeNewswire2 months ago

    Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

    Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Compensation Committee of the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 120,000 shares of its common stock to a new employee, with a grant date of October 8, 2018. The options will vest and become exercisable as to 25 percent of the shares on the one-year anniversary of the recipient's start date, and will vest and become exercisable as to the remaining 75 percent of the shares in 36 equal monthly installments at the end of each month following the anniversary, subject to the employee's continued employment with Marinus on such vesting dates.  The stock options were granted as inducements material to the new employee entering into employment with Marinus in accordance with NASDAQ Listing Rule 5635(c)(4), and are subject to the terms and conditions of a stock option agreement covering the grant.

  • GlobeNewswire2 months ago

    Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Compensation Committee of the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 20,000 shares of its common stock each to two new employees, with grant dates of October 1 and October 3, 2018. The stock options were granted as inducements material to the new employees entering into employment with Marinus in accordance with NASDAQ Listing Rule 5635(c)(4), and are subject to the terms and conditions of a stock option agreement covering the grant. Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders.

  • Simply Wall St.3 months ago

    What Kind Of Shareholders Own Marinus Pharmaceuticals Inc (NASDAQ:MRNS)?

    A look at the shareholders of Marinus Pharmaceuticals Inc (NASDAQ:MRNS) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge Read More...

  • GlobeNewswire3 months ago

    Marinus Completes Enrollment in its Magnolia Postpartum Depression Study

    Marinus Pharmaceuticals, Inc. (MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced it has recently completed enrollment in its Magnolia Study – a Phase 2 clinical trial evaluating the safety, pharmacokinetics and efficacy of ganaxolone in women with postpartum depression. “The completion of enrollment in our Magnolia Study is an important milestone in studying PPD, for which there is currently no approved treatment,” said Christopher Cashman, chairman and CEO of Marinus Pharmaceuticals.

  • ACCESSWIRE3 months ago

    Deals Pile Up as Big Biotech Looks to Capitalize on the Growing Market

    HENDERSON, NV / ACCESSWIRE / September 20, 2018 / Small biotech companies have been receiving a ton of interest this year. Just last week, Boehringer Ingelheim's shopping spree continued with a €210m takeover of ViraTherapeutics, an oncolytic virus specialist it has been working with since 2016. Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, has recently announced an amendment to its Registration trial in ocular melanoma liver metastases, a disease that has shown resistance to the new immunotherapies.

  • GlobeNewswire3 months ago

    Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Compensation Committee of the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 42,000 shares of its common stock to a new director and a new employee, with a grant date of September 19, 2018. Ganaxolone is a positive allosteric modulator of GABAA that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects.

  • 7 Biotech Stocks With Big Upcoming Catalysts
    Kiplinger4 months ago

    7 Biotech Stocks With Big Upcoming Catalysts

    Are you ready? Biotech stocks provide a compelling opportunity for risk-tolerant investors looking for rich rewards. Regardless of market sentiment, economic data or trade wars, a key regulatory approval or trial data can send prices rocketing. Consider Madrigal Pharma (MDGL), which exploded by nearly 150% back in May following positive Phase 2 results for a liver-disease treatment. Of course, the opposite can also be true - prices can fall just as quickly if data or approvals fail to impress. That's why it's so crucial to conduct thorough research before investing in this high-potential (but high-risk) area of the market. For instance, using TipRanks, we can assess both the analyst consensus rating (all the stocks covered below are a "Moderate Buy" or "Strong Buy") and the expected upside potential based on recent ratings. Here are seven biotech stocks that could be catapulted higher by near-term catalysts. We'll also explore the pros' analysis and price targets for each company. SEE ALSO: The 18 Best Stocks to Buy for the Rest of 2018